An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin - sprookjes - yvandenbroek - TriplyDB

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

http://www.wikidata.org/entity/Q27679463

about

Regulation of ERBB3/HER3 signaling in cancer Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk.Pseudokinases: update on their functions and evaluation as new drug targets.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice.ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)HER-3 targeting alters the dimerization pattern of ErbB protein family members in breast carcinomas.Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig™) proteins with unique activities.HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer.FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct.Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.Molecular pathways: HER3 targeted therapy Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy.HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.HER3/ErbB3, an emerging cancer therapeutic target.Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.The impact of structural biology in medicine illustrated with four case studies.HER3 as a Therapeutic Target in Cancer.The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.Pertuzumab and trastuzumab: the rationale way to synergy.A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.Discovery of ERBB3 inhibitors for non-small cell lung cancer (NSCLC) via virtual screening.

P2860

Q27024334-015D401F-85A7-4297-81FA-DF1F9426BEBA Q27315979-B30EE38E-9DD6-4E01-AAD0-346E71AF937F Q30397636-F193C63A-F7A7-4096-A03B-8C2AE64FCA1D Q33601653-C6AAE9B5-3DCE-4B57-A44A-7A431B1ED334 Q33610361-58CA39B9-A26D-4B8E-B277-A570CC8E1755 Q33772914-1D52057F-F1DC-4F47-928C-BDA9C297ABB3 Q34506951-F3C24C6A-3B0B-4485-917D-1C50E08AFF6E Q35168105-FA27ABFE-5429-40F0-B296-A18DF242942C Q35201923-7CCF2ABE-8147-41B4-97CB-FE7BB47A72F7 Q35682599-B9E76157-BC42-447C-885E-7FB09E5E3B40 Q35890128-30064F7D-B29D-4097-831F-E1DA04EA0093 Q36021891-EAE04CF9-68A5-4C5A-9A6D-97D1132D807E Q36115818-AB399BF0-A47A-4350-96CA-AAB69C5B4450 Q36238299-C7C1570F-0C08-4AAE-8524-C1D94349AB5D Q36619622-BBC0B6FD-4F10-481B-9F44-FD57960C8471 Q37013995-0847A487-826E-452D-BB9C-CCCFC2D9B36C Q37578368-90AFE641-6673-44B2-98BE-5F0737308F2D Q37622191-DBC11168-3BAE-4EB6-B34B-0B58DFF3E6B7 Q37660979-8FF2C00A-329D-45AD-B55D-D962A84F7298 Q37692080-E1900699-6AF9-42BC-A71E-A00130CB91CA Q38187398-1A3B5FD3-EB11-4D60-8EE4-7C9D7B91341D Q38214511-976151D7-D55B-4555-B078-B8A7CF215F40 Q38238616-60470B04-7A1D-4FF8-B336-3751E52C4B2D Q38301236-DAB0EB32-A989-41B8-ACAF-218403B8BF8F Q38355156-4A1F6A7F-B272-489B-B7A3-C7B38C13C7BC Q38364887-399F69BE-F142-4B4A-921B-FC01E5D2498B Q38615197-D17F78D6-86C2-42BF-9854-A2FE98BA5D81 Q38623361-7C5D5D50-DBCB-460E-A1EC-EA0EF314EFC1 Q38698199-5CE5921B-83EC-46E4-8349-8952B9E91DF3 Q38725101-5CC9F209-427F-41B8-AC58-3980D98FA368 Q38766447-496FBB9E-B689-469C-B015-6136324FE86F Q38876644-56C3EB4B-3B4F-4833-80F8-B82D24DD750C Q38929801-0DAC717A-9F8F-4558-8CC1-D1577B299DB6 Q39701009-CCC6A935-E2C2-48BB-9B54-DAFE96B283EB Q41173029-F78B0C23-4920-4D96-BFA5-22CC240F8BBD Q42558833-F37089C5-9486-4479-A63B-620F1B9343FC Q47158524-741F65D9-F498-400A-BD36-7E6F0DD91C05 Q47564950-7E037076-B29B-4783-9C92-2D65EA3FD3D0 Q47615981-422D0E75-772D-4CEF-A7D9-41DCC82D7386 Q50852401-08F956FB-226D-4D14-B3BA-CDEF095BD0AC

P2860

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

http://www.wikidata.org/entity/Q27679463

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

An Antibody That Locks HER3 in ...... h Driven by HER2 or Neuregulin

@ast

An Antibody That Locks HER3 in ...... h Driven by HER2 or Neuregulin

@en

An Antibody That Locks HER3 in ...... h Driven by HER2 or Neuregulin

@nl

type

label

An Antibody That Locks HER3 in ...... h Driven by HER2 or Neuregulin

@ast

An Antibody That Locks HER3 in ...... h Driven by HER2 or Neuregulin

@en

An Antibody That Locks HER3 in ...... h Driven by HER2 or Neuregulin

@nl

prefLabel

An Antibody That Locks HER3 in ...... h Driven by HER2 or Neuregulin

@ast

An Antibody That Locks HER3 in ...... h Driven by HER2 or Neuregulin

@en

An Antibody That Locks HER3 in ...... h Driven by HER2 or Neuregulin

@nl

P1433

Q27679463-9F858F8C-B53C-47C4-9413-7F887A7D4F1A

P1476

Q27679463-1DC78F5F-5717-4300-9FA6-4CF2AC80681E

P2093

Q27679463-13A1B95E-9B5F-425C-A371-46A95C2753AE

Q27679463-1738B030-DB28-43E3-BBB9-4214E8D5C133

Q27679463-18508570-1FDA-413A-9ADC-C661DF9E78E9

Q27679463-255F2357-99FF-4148-884F-2C2F8AEB9CF4

Q27679463-38ADD95C-B7D1-40F1-BC5F-E96ED1C4E37E

Q27679463-41131EEE-C6D2-4835-8CA8-CF7EF83000A3

Q27679463-503EC0F3-0D77-4354-A2A4-118DF8D9554D

Q27679463-60BB96F9-5388-4157-844A-0169E52B101F

Q27679463-630CF050-44B6-4884-AD28-5FB7F3E2C86F

Q27679463-6B2A28DB-07AB-442A-B662-AE0BFD31C202

P2860

Q27679463-09B89E08-C021-4843-B91B-9673162C2C61

Q27679463-0DAA9B66-C1FD-49A3-8A2A-E6DCB106E377

Q27679463-104D0562-43A4-4727-B7EC-996D5FE3B54E

Q27679463-2546B9DE-A0AE-438C-9559-43D3114A4FAF

Q27679463-270D6166-8C80-495C-8027-7953208E4EE7

Q27679463-2FC05AD1-4A35-456B-960A-3BDE91A7C56E

Q27679463-33C09476-8415-4CA2-AB8F-3ACDBF92D13A

Q27679463-35790ADA-B950-4953-8F53-5BCB8943157A

Q27679463-39B2C347-149E-476E-911C-CAAB2E792C4B

Q27679463-3AC13DE8-8E6B-4C47-A671-777942B0A7CD

P304

Q27679463-AAD4EE6D-35B9-4CB8-8223-D8CD55BCE9A2

P31

Q27679463-B239B3C6-58AF-4AF1-9D00-632D5E8220D8

P3181

Q27679463-1D597D24-0193-4921-854F-B6391CDF5BFA

P356

Q27679463-D05CE68C-1DB2-4079-8670-912CFD813BDD

P407

Q27679463-6D7B4E98-6084-4250-B477-65DC5FE61232

P433

Q27679463-02578602-E3AD-47C7-A433-08E908ADE795

P478

Q27679463-40239487-F93B-4FC0-821E-9CAF1F2552AA

P577

Q27679463-ACED2B88-47C8-460E-A5E5-6BE98BA2EB6C

P698

Q27679463-24DFEC05-8C81-4C33-B168-BB79EE502CD4

P921

Q27679463-22B244A6-3FEA-43FE-ADD8-F47788AE11A8

P932

Q27679463-3BC1AEA6-548D-4464-BF5D-C5C992C8AE17

P3181

P356

0008-5472.CAN-13-1198

P1433

Cancer Research

P1476

An Antibody That Locks HER3 in ...... h Driven by HER2 or Neuregulin

@en

P2093

Alan Huang

http://www.w3.org/2001/XMLSchema#string

Alwin Schuller

http://www.w3.org/2001/XMLSchema#string

Analeah B Heidt

http://www.w3.org/2001/XMLSchema#string

Andrew P Garner

http://www.w3.org/2001/XMLSchema#string

Cammie R Sutton

http://www.w3.org/2001/XMLSchema#string

Carl U Bialucha

http://www.w3.org/2001/XMLSchema#string

Carlos L Arteaga

http://www.w3.org/2001/XMLSchema#string

Carolin Zehetmeier

http://www.w3.org/2001/XMLSchema#string

Christian Kunz

http://www.w3.org/2001/XMLSchema#string

Dongshu Chen

http://www.w3.org/2001/XMLSchema#string

P2860

EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells

Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Somatic mutations affect key pathways in lung adenocarcinoma

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

P304

6024-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1339505

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/0008-5472.CAN-13-1198

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23928993

http://www.w3.org/2001/XMLSchema#string

P921

P932

3924863

http://www.w3.org/2001/XMLSchema#string